MA29458B1 - Composition de vaccin - Google Patents

Composition de vaccin

Info

Publication number
MA29458B1
MA29458B1 MA30386A MA30386A MA29458B1 MA 29458 B1 MA29458 B1 MA 29458B1 MA 30386 A MA30386 A MA 30386A MA 30386 A MA30386 A MA 30386A MA 29458 B1 MA29458 B1 MA 29458B1
Authority
MA
Morocco
Prior art keywords
vectors
adenoviruses
adenovirus
hiv
virus
Prior art date
Application number
MA30386A
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Wely Catherine Ann Van
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29458(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29458B1 publication Critical patent/MA29458B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR DES VECTEURS DE VIRUS COMPRENANT DES OLIGONUCLÉOTIDES CODANT DES POLYPEPTIDES VIH ET PLUS PARTICULIÈREMENT SUR UN VECTEUR DE VIRUS QUI EST UN ADÉNOVIRUS. CES ADÉNOVIRUS SONT EN PARTICULIER DES ADÉNOVIRUS DE PRIMATES NON HUMAINS TELS QUE DES ADÉNOVIRUS DE SINGES, PLUS PRÉCISÉMENT DES ADÉNOVIRUS DE CHIMPANZÉS. CETTE INVENTION CONCERNE EN PARTICULIER DES VECTEURS D'ADÉNOVIRUS QUI COMPRENNENT DES SÉQUENCES DE POLYNUCLÉOTIDES VIH QUI CODENT DE MULTIPLES ANTIGÈNES VIH DIFFÉRENTS, PAR EXEMPLE AU MOINS DEUX OU TROIS ANTIGÈNES VIH. CETTE INVENTION CONCERNE ÉGALEMENT DES MÉTHODES DE PRÉPARATION DES VECTEURS DE VIRUS, LES VECTEURS DE VIRUS PRODUITS PAR CES MÉTHODES ET L'UTILISATION DE CES VECTEURS EN MÉDECINE, EN PARTICULIER DANS LA VACCINATION PROPHYLACTIQUE OU THÉRAPEUTIQUE.
MA30386A 2005-05-12 2007-11-20 Composition de vaccin MA29458B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68038905P 2005-05-12 2005-05-12

Publications (1)

Publication Number Publication Date
MA29458B1 true MA29458B1 (fr) 2008-05-02

Family

ID=36954770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30386A MA29458B1 (fr) 2005-05-12 2007-11-20 Composition de vaccin

Country Status (20)

Country Link
US (1) US20090208515A1 (fr)
EP (1) EP1880012B1 (fr)
JP (2) JP5175178B2 (fr)
KR (1) KR101451620B1 (fr)
CN (2) CN101384722A (fr)
AR (1) AR053275A1 (fr)
AU (1) AU2006245920A1 (fr)
BR (1) BRPI0608798A2 (fr)
CA (1) CA2608316A1 (fr)
EA (1) EA200702190A1 (fr)
ES (1) ES2546330T3 (fr)
IL (1) IL186828A (fr)
MA (1) MA29458B1 (fr)
MX (1) MX2007014038A (fr)
NO (1) NO20075648L (fr)
PE (1) PE20061372A1 (fr)
SG (1) SG182173A1 (fr)
TW (1) TW200716750A (fr)
WO (1) WO2006120034A1 (fr)
ZA (1) ZA200709518B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209133B1 (pl) 2001-11-21 2011-07-29 Univ Pennsylvania Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie
WO2008027394A2 (fr) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Construction permettant d'augmenter les réponses immunitaires
MX362698B (es) * 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CN101883857B (zh) * 2007-11-28 2015-08-12 宾夕法尼亚大学托管会 猿猴亚家族B腺病毒SAdV-28、-27、-29、-32、-33和-35及其应用
KR101662574B1 (ko) * 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CA2716928C (fr) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Adenovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
RU2609769C2 (ru) 2011-04-06 2017-02-02 Биоваксим Лимитед Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2873509A1 (fr) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Adenovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
JP2016513666A (ja) * 2013-03-14 2016-05-16 アムジエン・インコーポレーテツド 組織メタロプロテイナーゼ阻害物質３型（ｔｉｍｐ−３）の変異体、組成物、及び方法
EP3271729B1 (fr) 2015-03-18 2020-09-23 Janssen Vaccines & Prevention B.V. Essais pour des systèmes d'expression recombinants
SI3283634T1 (sl) 2015-04-14 2019-08-30 Janssen Vaccines & Prevention B.V. Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
AU2016275619B2 (en) * 2015-06-12 2019-09-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
US10343884B2 (en) 2015-07-10 2019-07-09 E. & J. Gallo Winery System and method for dispensing a beverage
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
CN109804075A (zh) 2016-08-01 2019-05-24 威斯塔解剖学和生物学研究所 用于疫苗应用的复制缺陷型腺病毒载体的组合物和方法
WO2018146205A1 (fr) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Promoteur puissant et court pour l'expression de gènes hétérologues

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
JP2005523233A (ja) * 2001-06-22 2005-08-04 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー 細胞障害性免疫応答を誘導する方法およびその方法において有用な組み換えサル・アデノウイルス組成物
CA2461056A1 (fr) * 2001-09-20 2003-03-27 Glaxo Group Limited Vaccins
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP1682666B1 (fr) * 2003-09-24 2008-12-31 Oxxon Therapeutics Limited Vaccins pharmaceutiques contre le vih
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
MX2007014038A (es) 2008-02-11
JP5175178B2 (ja) 2013-04-03
CA2608316A1 (fr) 2006-11-16
ES2546330T3 (es) 2015-09-22
AU2006245920A1 (en) 2006-11-16
WO2006120034A1 (fr) 2006-11-16
SG182173A1 (en) 2012-07-30
ZA200709518B (en) 2014-01-29
CN103088060A (zh) 2013-05-08
TW200716750A (en) 2007-05-01
PE20061372A1 (es) 2007-01-16
IL186828A (en) 2015-06-30
NO20075648L (no) 2008-02-07
KR101451620B1 (ko) 2014-10-21
US20090208515A1 (en) 2009-08-20
EP1880012A1 (fr) 2008-01-23
BRPI0608798A2 (pt) 2011-03-15
CN101384722A (zh) 2009-03-11
EP1880012B1 (fr) 2015-07-08
WO2006120034A8 (fr) 2007-11-15
JP2008539746A (ja) 2008-11-20
EA200702190A1 (ru) 2008-04-28
KR20080021659A (ko) 2008-03-07
JP2013046613A (ja) 2013-03-07
IL186828A0 (en) 2008-02-09
AR053275A1 (es) 2007-04-25

Similar Documents

Publication Publication Date Title
MA29458B1 (fr) Composition de vaccin
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
NO20035740D0 (no) Fremgangsmåter for å indusere en cytotoksisk immunrespons og rekombinante ape-adenovirussammensetninger nyttige for disse
HUP0301835A2 (hu) Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
MA32018B1 (fr) Vaccin
MA30671B1 (fr) Vaccins contre le paludisme
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
MA32030B1 (fr) Vaccins anti-malaria
WO2003035695A3 (fr) Agents pouvant activer ou inhiber le recepteur 9 de type toll
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
BR0109502A (pt) Molécula de interesse farmacêutico, composição farmacêutica, vacina, método de diagnóstico in vitro de patologias associadas com a presença em um corpo de paciente de ligandos do mhc, pacote ou kit para execução de métodos de diagnóstico in vitro, utilizações de um ligando e de um ácido forte, e, processo de preparação e de estabilização de uma molécula de interesse farmacêutico
HUP0302790A2 (hu) SI (Helicobacter pylori) receptorok és alkalmazásuk
HUP0400840A2 (hu) Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2004110373A3 (fr) Compositions vaccinales therapeutiques servant a traiter le diabete de type 1
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
Desai et al. Platform switching: A panacea for bone loss??
DK1449535T3 (da) Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1